Review of drugs for Alzheimer's disease

Drug Discoveries & Therapeutics

Volumn 6, Issue 6, 2011, Pages 285-290

  Sun, Xiaoting ^a   Jin, Lan ^a   Ling, Peixue ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b Institute of Biopharmaceuticals of Shandong Province   (China)

Author keywords

Alzheimer's disease; drugs; treatment

Indexed keywords

EID: 85008744636     PISSN: 18817831     EISSN: 1881784X     Source Type: Journal    
DOI: 10.5582/ddt.2012.v6.6.285     Document Type: Article

References (50)

1. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Karlawish J, Hurtig HI, Siderowf A, Lee VM, Soares H, Trojanowski JQ. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol. 2010; 120:385-399.
2. Forlenza OV, Diniz BS, Gattaz WF. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med. 2010; 8:89-102.
3. Sabbagh M, Cummings J. Progressive cholinergic decline in Alzheimer's disease: Consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011; 11:21-26.
4. Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain. 2011; 4:3-15.
5. Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol. 2010; 8:69-80.
6. Amatsubo T, Yanagisawa D, Morikawa S, Taguchi H, Tooyama I. Amyloid imaging using high-field magnetic resonance. Magn Reson Med Sci. 2010; 9:95-99.
7. Wang JM, Sun C. Calcium and neurogenesis in Alzheimer's disease. Front Neurosci. 2010; 4:194-198.
8. Coppede F. One-carbon metabolism and Alzheimer's disease: Focus on epigenetics. Curr Genomics. 2010; 11:246-260.
9. Wollen KA. Alzheimer's disease: The pros and cons of pharmaceutical, nutritional, botanical, and stimulatory therapies, with a discussion of treatment strategies from the perspective of patients and practitioners. Altern Med Rev. 2010; 15:223-244.
10. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progressing of Alzheimer's disease: Therapeutic implications. Expert Rev Neurother. 2008; 8:1703-1718.
11. Watanabe T, Iwasaki K, Ishikane S, Naitou T, Yoshimitsu Y, Yamagata N, Ozdemir MB, Takasaki K, Egashira N, Mishima K, Fujiwara M. Spatial memory impairment without apoptosis induced by the combination of β-amyloid oligomers and cerebral ischemia is related to decreased acetylcholine release in rats. J Pharmacol Sci. 2008; 106:8491.
12. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010; 23:213-227.
13. Pagani L, Eckert A. Amyloid-β interaction with mitochondria. Int J Alzheimers Dis. 2011; 10:1-11.
14. Li T, Zhao ZX. β-Amyloid and Alzheimer disease: Recent progress. Acad J Second Mil Med Univ. 2010; 31:11331137.
15. He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. Curr Neuropharmacol. 2010; 8:211-217.
16. Ondrejcak T, Klyubin I, Hu NW, Barry AE, Cullen WK, Rowan MJ. Alzheimer's disease amyloid β-protein and synaptic function. Neuromolecular Med. 2010; 12:13-26.
17. Giaccone G, Pedrotti B, Miqheli A, et al. PPP and Tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease. Am J Pathol. 1996; 148:79-87.
18. Armstrong RA. The pathogenesis of Alzheimer's disease: A reevaluation of the “amyloid cascade hypothesis”. Int J Alzheimers Dis. 2011; 10:1-6.
19. Supnet C, Bezprozvanny I. Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease. J Alzheimers Dis. 2010; 20:487-498.
20. Itkin A, Dupres B, Dufrene YF, Bechinger B, Ruysschaert JM, Raussens V. Calcium ions promote formation of amyloid β-peptide (1-40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One. 2011; 6:1-10.
21. Ramberg V, Tracy LM, Samuelsson M, Nilsson LN, Iverfeldt K. The CCAAT/enhancer binding protein (C/EBP) δ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-β peptide. J Neuroinflammation. 2011; 8:34-60.
22. Lei LW, Wang Y Progress of pathogenesy and inflammation in Alzheimer's disease. Med Recap. 2008; 14:3041-3043.
23. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain-barrier model. J Biol Chem. 2011; 286:17536-17542.
24. Altman R, Rutledge JC. The vascular contribution to Alzheimer's disease. Clin Sci. 2010; 119:407-421.
25. Bates KA, Sohrabi HR, Rodrigues M, et al. Association of cardiovascular factors and Alzheimer's disease plasma amyloid-β protein in subjective memory complainers. J Alzheimers Dis. 2009; 17:305-318.
26. Zhuang Y, Chen J. Research process on causes and mechanism of Alzheimer's Disease. J Jilin Med Col. 2008; 29:101-104.
27. Kawahara M, Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer's disease: The integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis. 2011; 10:1-17.
28. Mutter J, Curth A, Naumann J, Deth R, Walach H. Does inorganic mercury play a role in Alzheimer's disease? A systematic review and an integrated molecular mechanism. J Alzheimers Dis. 2010; 22:357-374.
29. Wu TY, Chen CP, Jinn TR. Alzheimer's disease: Aging, insomnia and epigenetics. Taiwan J Obstet Gynecol. 2010; 49:468-472.
30. Aranda-Abreu GE, Hernandez-Aquilar ME, Denes JM, Garcia Hernandez LI, Rivero MH. Rehabilitating a brain with Alzheumer's: A proposal. Clin Interv Aging. 2011; 6:53-59.
31. Benjamin B, Burns A. Donepezil for Alzheimer's disease. Expert Rev Neurother. 2007; 7:1243-1249.
32. Kurz A, Farlow M, Lefevre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review. Int J Clin Pract. 2009; 63:799-805.
33. Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010; 25:627-633.
34. Ago Y, Koda K, Takuma K, Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci. 2011; 116:6-17.
35. Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. Clin Interv Aging. 2010; 5:1-6.
36. Zheng R, Su YF. Research progress of clinical use of Huperzine A. Pract Pharm Clin Remedies. 2008; 11:107108.
37. Jakubik J, Michal P, Machova E, Dolezal V. Importance and prospects for design of selective muscarinic agonists. Physiol Res. 2008; 57(Suppl 3):39-47.
38. Disterhoft JF, Oh MM. Pharmacological and molecular enhancement of learning in aging and Alzheimer's disease. J Physiol Paris. 2006; 99:180-192.
39. Lopez-Arrieta JM, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 2002; 3:CD000147.
40. Mas E, Dupuy AM, Artero S, Portet F, Cristol JP, Ritchie K, Touchon J. Functional vitamin E deficiency in ApoE4 patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 21:198-204.
41. DelaGarza VW. Pharmacologic treatment of Alzheimer's disease: An update. Am Fam Physician. 2003; 68:13651372.
42. Wang X. The anti-apoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci Ther. 2009; 15:345-357.
43. Esposito E, Cuzzocrea S. Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol. 2010; 8:228-242.
44. He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. Curr Neuropharmacol. 2010; 8:211-217.
45. Krause DL, Muller N. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int J Alzheimers Dis. 2010; 10:1-9.
46. Davies P, Koppel J. Mechanism-based treatment for Alzheimer's disease. Dialogues Clin Neurosci. 2009; 11:159169.
47. Liu G, Men P, Perry G, Smith MA. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol. 2010; 610:123-144.
48. Oshiro S, Morioka MS, Kikuchi M. Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Adv Pharmacol Sci. 2011; 10:1155-1163.
49. Xing XN, Zhang WG, Sha S, Li Y, Guo R, Wang C, Cao YP. Amyloid β 3-10 DNA vaccination suggests a potential new treatment for Alzheimer's disease in BALB/c mice. Chin Med J (Engl). 2011; 124:2636-2641.
50. Xing XN, Zhang WG, Sha S, Li Y, Guo R, Wang C, Cao YP. Amyloid β3-10 DNA vaccination suggests a potential new treatment for Alzheimer's disease in BALB/c mice. Chin Med J. 2011; 124:2636-2641.